Amylyx Pharmaceuticals
AMLX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +219.6% in FY2025
Joshua Cohen is the CEO of Amylyx Pharmaceuticals and was paid $2.7M in FY2025 (Dec), down 58%.
Pay$100 in the stock at the end of FY22 → $11
Executives4
See all- 1Joshua CohenCo-Chief Executive Officer and DirectorFY2025
- 2Justin KleeCo-Chief Executive Officer and DirectorFY2025
- 3Camille L. Bedrosian, M.D.Chief Medical OfficerFY2025
- 4James FratesChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allAmylyx Pharmaceuticals paid its 4 named executives $8.4M in total in FY2025 (Dec). CEO Joshua Cohen was paid $2.7M of that.
| Name | |||
|---|---|---|---|
| Joshua CohenCo-Chief Executive Officer and Director | |||
| Justin KleeCo-Chief Executive Officer and Director | |||
| Camille L. Bedrosian, M.D.Chief Medical Officer | Not disclosed | ||
| James FratesChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Karen FirestoneDirector · 2 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 24, 2025 | FY2024 |
| Annual report | 10-K | Mar 4, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 24, 2024 | FY2023 |
| Annual report | 10-K | Feb 22, 2024 | FY2023 |
